Prophase Labs Stock Today
| PRPH Stock | USD 0.45 0.04 8.67% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
ProPhase Labs is trading at 0.4475 as of the 26th of February 2025. This is a 8.67 percent decrease since the beginning of the trading day. The stock's open price was 0.49. ProPhase Labs has about a 44 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 28th of November 2024 and ending today, the 26th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of January 1997 | Category Healthcare | Classification Health Care |
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter consumer healthcare products and dietary supplements in the United States. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. The company has 30.23 M outstanding shares of which 84.87 K shares are at this time shorted by private and institutional investors with about 0.19 trading days to cover. More on ProPhase Labs
Moving together with ProPhase Stock
Moving against ProPhase Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
ProPhase Stock Highlights
| Chairman and CEO | Ted Karkus | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Management, Management, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsProPhase Labs can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ProPhase Labs' financial leverage. It provides some insight into what part of ProPhase Labs' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ProPhase Labs (PRPH) is traded on NASDAQ Exchange in USA. It is located in 711 Stewart Avenue, Garden City, NY, United States, 11530 and employs 113 people. ProPhase Labs is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 14.75 M. ProPhase Labs conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 30.23 M outstanding shares of which 84.87 K shares are at this time shorted by private and institutional investors with about 0.19 trading days to cover.
ProPhase Labs currently holds about 27.5 M in cash with (11.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check ProPhase Labs Probability Of Bankruptcy
Ownership AllocationProPhase Labs owns a total of 30.23 Million outstanding shares. ProPhase Labs holds 11.15 pct. of its outstanding shares held by insiders and 8.31 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check ProPhase Ownership Details
ProPhase Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bank Of New York Mellon Corp | 2024-12-31 | 37.1 K | |
| Northern Trust Corp | 2024-12-31 | 36.7 K | |
| Bank Of America Corp | 2024-12-31 | 36.7 K | |
| United Capital Management Of Ks | 2024-12-31 | 34.7 K | |
| T. Rowe Price Associates, Inc. | 2024-12-31 | 17.3 K | |
| Two Sigma Securities, Llc | 2024-12-31 | 16.4 K | |
| Engineers Gate Manager Lp | 2024-12-31 | 16 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 9.2 K | |
| Jpmorgan Chase & Co | 2024-09-30 | 3.6 K | |
| Vanguard Group Inc | 2024-12-31 | 655 K | |
| Renaissance Technologies Corp | 2024-12-31 | 286.5 K |
ProPhase Labs Historical Income Statement
ProPhase Stock Against Markets
ProPhase Labs Corporate Management
| Billy White | Consultant | Profile | |
| Lance Bisesar | Corporate Controller | Profile | |
| Robert Morse | Principal Controller | Profile | |
| Stu Hollenshead | Chief Officer | Profile | |
| Sergio Miralles | Executive Diagnostics | Profile | |
| Kamal Obbad | Senior Genomics | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProPhase Labs. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProPhase Labs. If investors know ProPhase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (1.53) | Revenue Per Share | Quarterly Revenue Growth (0.62) | Return On Assets |
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProPhase Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProPhase Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProPhase Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.